Support The World's Smartest Network

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Disrupting Protein–Protein Interactions with Small Molecules

Disrupting Protein–Protein Interactions with Small Molecules

Tuesday, February 7, 2006

The New York Academy of Sciences

Presented By


Organizer: Andras Bauer and Brent Stockwell, Columbia University

Recent years have seen an increasing level of dialogue between chemists and biologists, the lines of communication consolidated by the availability of recombinant biotechnology tools for manipulating the chemical structure of genes, and the proteins they encode. This has led to an explosion of interdisciplinary activity at the chemistry/biology interface, now coined chemical biology. Meetings of this group provides a forum for lively discussion and for establishing connections, and perhaps collaborations, between chemists armed with novel technologies and biologists receptive to using these approaches to solve their chosen biological problem.


4:00 - 6:00: Presentations

Andras Bauer
, Columbia University

Loren D. Walensky, Dana Farber Cancer Institute/Children's Hospital Boston, "Targeting Protein Interactions in Vivo Using Hydrocarbon-Stapled Peptide Helices."

Ramesh Shivdasani, Dana-Farber Cancer Institute, Harvard Medical School, "Chemical Targeting of Protein-Protein Interactions in Cancer Therapy."


"Targeting Protein Interactions in Vivo Using Hydrocarbon-Stapled Peptide Helices"
Loren D. Walensky

Protein interactions are fundamental to the regulation of biological control points that sustain cellular homeostasis. The BCL-2 family of proteins regulates apoptosis, or programmed cell death, through a complex network of protein-protein interactions that dictate cell fate. Indeed, a wide spectrum of human diseases directly results from faulty regulation of apoptosis, leading to premature cell death or unchecked cellular survival. Protein interaction among BCL-2 proteins is mediated through an alpha helical segment termed BH3, which functions as an essential death domain. Because natural peptides display evolutionarily-honed binding specificity, synthetic peptides of the BCL-2 family offer the potential to selectively disrupt or activate these "life-and-death" protein interactions. However, the utility of peptides as biological reagents and prototype therapeutics has been severely compromised by their lack of biologically-active structure, susceptibility to degradation, and difficulty entering cells. Our research focuses on developing and applying new approaches to chemically brace natural peptides so that their shape, and therefore their biological activity, can be restored. We applied a novel chemical strategy, termed "hydrocarbon-stapling", to generate a panel of BCL-2 peptides with improved pharmacologic properties. The stapled peptides proved to be helical, protease-resistant, and capable of entering and killing leukemia cells by activating their death pathway. When administered to mice with leukemia, a stapled BCL-2 peptide successfully blocked cancer growth and prolonged the lives of treated animals. Our ongoing work involves the development of a chemical toolbox of hydrocarbon-stapled peptides to study and target pathologic signaling pathways in human cancer.

"Chemical Targeting of Protein-Protein Interactions in Cancer Therapy"
Ramesh Shivdasani

Colorectal cancer is a major cause of death in the West and currently is treated by surgical intervention if detected early or with limited success by traditional chemotherapy in advanced disease. The distinct molecular events that underlie pathogenesis of this disease are known in some detail. We designed studies to screen chemical compounds that disrupt the interaction between two proteins, Tcf4 and beta-catenin, that form a critical oncogenic complex. Selected compounds interfered with formation or stability of Tcf4/beta-catenin complexes in multiple laboratory tests, including growth of colorectal cancer cells grown in tissue culture. Such compounds validate the strategy of targeting protein-protein